VolitionRx gets NYSE lifeline to fix its $6 million equity gap

VolitionRx Limited (VNRX) received approval for its compliance plan from the NYSE American exchange, granting the company until August 6, 2027, to address a stockholders' equity deficit of up to $6 million and maintain its listing.

"The Acceptance Letter has no immediate impact on the listing of the Company's shares of common stock, which will continue to be listed and traded," VolitionRx said in a statement, confirming operations and SEC reporting are unaffected.

The exchange had found VolitionRx non-compliant on February 6, 2026, as its stockholders' equity fell below the required minimums of $2 million, $4 million, and $6 million for companies with losses in the last two, three, and five years, respectively. The stock, which closed Tuesday at $0.1577, remains near its 52-week low of $0.15, with trading volume at just 23% of its 20-day average ahead of the news.

With the immediate threat of delisting removed, the focus now shifts to VolitionRx's ability to execute its plan and rebuild its equity base before the August 2027 deadline. Investor sentiment has been cautious, with recent positive news on product launches and funding failing to lift the stock, suggesting this compliance issue was a significant overhang.

The core of the issue lies in Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide. These rules are designed to ensure listed companies maintain a minimum level of financial stability. VolitionRx, an epigenetics company developing blood tests for diseases like cancer, has incurred losses as it invests in research and commercialization, causing its equity to fall below the required thresholds. The company's plan, submitted before the March 8, 2026 deadline, outlines the actions it will take to bolster its equity, which will be subject to periodic review by the exchange.

The plan's acceptance provides critical breathing room. Despite a series of positive announcements in the prior month—including a new webshop launch, improved full-year 2025 financials, and €2.0 million in non-dilutive funding—the stock has not responded positively. This pattern suggests that the market's primary concern was the risk of delisting, which can severely impact a stock's liquidity and investor confidence. Peers like IceCure Medical (ICCM) and Apyx Medical (APYX) have shown mixed performance, indicating VNRX's challenges are company-specific. Failure to make sufficient progress or meet the final 2027 deadline could result in the NYSE American initiating delisting proceedings.

This article is for informational purposes only and does not constitute investment advice.